UBA1 and ovarian cancer: Similarly, high expression of UBA1 correlated with poor overall survival in lung and gastric cancer patients previously treated with chemotherapeutic drugs (176 and 153 patients, respectively), and with progression-free survival in ovarian cancer patients particularly treated with paclitaxel (229 patients) (Figure 8A).